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Objective. To demonstrate the antinociceptive eﬀect of lercanidipine in paclitaxel-induced neuropathy model in rat. Materials and
Methods.Atotalof30ratsweredividedintoﬁvegroupsofsixratsineachgroupasfollows:GrI:0.9%NaCl,GrII:paclitaxel+0.9%
NaCl, Gr III: paclitaxel+lercanidipine 0.5μg/kg, Gr IV: paclitaxel+lercanidipine 1μg/kg, and Gr V: paclitaxel+lercanidipine
2.5μg/kg.Paclitaxel-induced neuropathicpaininratwasproducedbysingleintraperitoneal(i.p.)injectionof1mg/kgofpaclitaxel
on four alternate days (0, 2, 4, and 6). The tail ﬂick and cold allodynia methods were used for assessing the pain threshold, and
the assessments were done on days 0 (before ﬁrst dose of paclitaxel) and on days 7, 14, 21, and 28. Results. There was a signiﬁcant
decrease (P<0.001) in the tail ﬂick and cold allodynia latency in the paclitaxel-alone group from day 14 onward when compared
withday0.Inthelercanidipinegroups,thedecreaseinthetailﬂickandcoldallodynialatencywasnotobservedin1.0and2.5μg/kg
groups and it was statistically signiﬁcant (P<0.01) when compared with paclitaxel-alone group.
1.Introduction
Neuropathicpainisatypeofpainwhichiscausedbydamage
to or dysfunction of the nervous system. [1] Neuropathic
pain cannot be explained by a single disease process or a
single speciﬁc location of damage. It is a disorder in the
structure and function of peripheral, motor, sensory, and/or
autonomicneuronseitherpartiallyorcompletely[2].Neuro-
pathic pain may be divided into peripheral, central, or mixed
(peripheral and central) neuropathic pain. As much as 7% to
8% of the population is aﬀected and in 5%, it may be severe
[3].
In order to evaluate the mechanisms of neuropathic pain
and to ﬁnd new therapeutic approaches, diﬀerent experimental
neuropathic pain models have been developed which include
chronic constriction injury of sciatic nerve, partial sciatic nerve
ligation, and partial transaction of sciatic nerve. Current
knowledge regarding the mechanisms of neuropathic pain
is incomplete and is biased by a focus on animal models of
peripheral nerve injury, and the treatment is often unsatis-
factory. It is an area of largely unmet therapeutic need. The
current pharmacological mainstays of clinical management
are tricyclic antidepressants and certain anticonvulsants, but
these only achieve clinically signiﬁcant (>50%) pain relief
in 40–60% of patients and are associated with several side
eﬀects. Opioids are generally considered to be less eﬀective
in neuropathic pain than in inﬂammatory pain [4].
Paclitaxel, a commonly used antineoplastic drug can pro-
duce a dose-limiting painful peripheral neuropathy when given
intraperitoneally and can be used as a model of peripheral neu-
r o p a t h yt oe v a l u a t et h ee ﬀect of various drugs in neuropathic
pain [5].
Lercanidipine is a third-generation L-type calcium chan-
nel blocker (CCB) belonging to the class dihydropyridines
and is approved for the treatment of cardiovascular disor-
ders. Various preclinical studies point to an altered role of
voltage-gated Ca2+ channels, particularly the α-2 delta sub-
unit after neuropathy, and speciﬁc blockers have been shown
to diﬀerentially attenuate the behavioural hypersensitivities
and altered dorsal horn neuronal responses that accompany
experimental neuropathic pain. The studies done to evaluate
the action of CCBs on CNS are quite limited [6].
In the published literatures, there is no data available
regarding the modulation of paclitaxel-induced neuropathic2 Pain Research and Treatment
painbylercanidipine.Hence,thepresentstudyisundertaken
to validate the model of neuropathic pain induced by pacli-
taxel and the eﬀect of lercanidipine in this model of neuro-
pathic pain.
2.MaterialsandMethods
2.1. Animals. Animals (Wistar rats weighing between 150–
180gm) were procured from the central animal house of
Postgraduate Institute of Medial Education and Research
(PGIMER), Chandigarh. They were kept individually in
polypropylene cages in an environmentally controlled room
of the departmental animal house. They were maintained
at 25 ± 2◦C with a 12-hour dark/light cycle and 40–70%
humidity. The animals had free access to food and water
and were fed with standard rat chow diet. Experiments were
carried out after a week of acclimatization according to the
guidelines of Animal Ethics Committee of the Institute and
the Committee for the Purpose of Control and Supervision
ofExperimentationinAnimals(CPCSEA)guidelinesforani-
mal care. Approval from the Institute’s Animal Ethics Com-
mittee was taken prior to conducting the studies. Extreme
care was taken to minimize the pain and discomfort to the
animals.
2.2. Drugs and Chemicals. Paclitaxel (Sigma Chemical Com-
pany, St. Louis, USA) and lercanidipine (Ranbaxy, Delhi,
India)werepurchasedforthestudyinthepurepowderform.
All the chemicals to be used in the experiment were of AR
grade from reputed suppliers. All the drugs and chemicals
were used as freshly prepared solutions and suspension. The
solutions of paclitaxel were made in Dimethyl Sulfoxide
(DMSO), and the solutions of lercanidipine were made in
methanol.
2.3.ExperimentalGroups. Atotalof30ratsweredividedinto
ﬁve groups of six rats in each group as follows: Gr I: 0.9%
NaCl, Gr II: paclitaxel +0.9% NaCl, Gr III: paclitaxel + lerca-
nidipine 0.5μg/kg, and Gr IV: paclitaxel + lercanidipine
1μg/kg, Gr V: paclitaxel + lercanidipine 2.5μg/kg.
2.4. Paclitaxel-Induced Neuropathic Pain in Rat [5]. In this
model, young Wistar rats were administered single intraperi-
toneal (i.p.) injection of 1mg/kg of paclitaxel on four alter-
nate days (0, 2, 4, and 6). The volume of injection was kept
constant at 1mL/kg. This model typically presents sensory
neuropathy. The tail ﬂick and cold allodynia methods were
used for assessing the pain threshold, and the assessments
were done on days 0 (before ﬁrst dose of paclitaxel) and on
days 7, 14, 21, and 28.
2.5. Treatment Protocol. As control, group I animals received
only the normal diet with 0.9% NaCl alone and group II
animals received Paclitaxel and 0.9% NaCl. From groups III
to V, animals were administered single i.p. injection of Lerca-
nidipine at doses of 0.5μg/kg, 1μg/kg and 2.5μg/kg, respec-
tively, from day 0 to 7 (for 8 consecutive days) along with
paclitaxel. All the animals were tested for heat and cold. The
tail ﬂick test was done around 10.00 Am, and then tail cold
allodynia test was done around 12.00 PM. On day 7 intraper-
itoneal injection of lercanidipine was given at 8.00 AM and
tail ﬂick test was done around 10.00 AM and then tail cold
allodynia test was done around 12.00 PM.
2.6. Assessment of Nociceptive Thresholds
2.6.1. Tail Flick Method [7]. For this, analgesiometer (Tech-
no, India) was used. The terminal (junction between proxi-
mal 2/3 and distal 1/3) portion of the tail was kept at 0.5cm
above the heated tantalums wire, and time to ﬂick and re-
move the tail was noted. The tail was not kept for more than
20 seconds to avoid burn injury.
2.6.2. Tail Cold Allodynia [8]. It was measured by immersing
thetipofthetailinice-cold(4◦C)waterandtuningthelaten-
cy to a withdrawal reﬂex. A cut of latency of 20 seconds was
kept to avoid any injury.
2.7. Statistical Analysis. The data was expressed as mean ±
SD. Data were analyzed by using multiple comparisons
ANOVA followed by Tukey’s HSD test. Comparisons were
made between test and control groups. A P value less than
0.05 was considered statistically signiﬁcant.
3. Results
Paclitaxel-induced neuropathy was seen at 14 day. Decreased
in latency was observed in tail ﬂick and cold allodynia, and
it was persisted till 28 days. No other abnormal behavioural
response was seen. The eﬀect of lercanidipine at various
doses on tail ﬂick and cold allodynia latency is presented in
Tables 1 and 2. There was a signiﬁcant decrease (P<0.001)
in the tail ﬂick and cold allodynia latency in the paclitaxel-
alone group from day 14 onward when compared with day 0.
In the lercanidipine groups, the decrease in the tail ﬂick and
cold allodynia latency was not observed in 1.0 and 2.5μg/kg
groups and it was statistically signiﬁcant (P<0.01) when
compared with paclitaxel alone group. At 0.5μg/kg dose,
lercanidipinewasnoteﬀectiveinpreventingneuropathypro-
duce by paclitaxel.
4. Discussion
Neuropathic pain is deﬁned as “pain initiated or caused by
a primary lesion or dysfunction in the nervous system”. [1]
Neuropathic pain may be divided into peripheral, central, or
mixed (peripheral and central) neuropathic pain. As much
as 7% to 8% of the population is aﬀected and in 5%, it
may be severe [3]. Unique to oncology is the role of chemo-
therapy-induced damage to peripheral sensory neurons.
The precise mechanisms are unknown and likely vary with
the chemotherapeutic agent administered. However, recent
advancesinthelaboratoryprovidesomeinformationregard-
ing the damage incurred to the nervous system. For exam-
ple, paclitaxel administered to rats produces symptoms of
peripheral neuropathy similar to those seen in humans, in-
cluding hyperalgesia (an increased response to stimuli thatPain Research and Treatment 3
Table 1: Eﬀect of lercanidipine in various doses on Tail ﬂick latency (second) in paclitaxel-induced neuropathic rats. Data are expressed as
mean ± SD.
Day Control (n = 6) Paclitaxel
1mg/kg(n = 6)
Lercanidipine
0.5μg/kg (n = 6)
Lercanidipine
1.0μg/kg (n = 6)
Lercanidipine
2.5μg/kg (n = 6)
01 0 .19 ±0.73 13 ±1.55 12.89 ±1.63 11.11 ±1.52 11.17 ±1.28
71 0 .83 ±1.26 11.72 ±1.22 12.06 ±0.83 12.00 ±1.19 10.25 ±0.87
14 10.72 ±1.27 9.6 ±1.02∗ 10.72 ±1.31∗ 12.44 ±2.04# 12.05 ±.75#
21 10.97 ±1.31 8.86 ±0.98∗ 10.33 ±1.31∗ 13.56 ±1.93# 11.78 ±2.05#
28 10.72 ±2.04 8.36 ± .64
∗ 9.5 ±.68
∗ 12.67 ±1.05# 12.44 ±1.38#
∗P < 0.001 compared to 0 day, #P<0.01 compared to paclitaxel group.
Table 2: Eﬀect of lercanidipine in various doses on cold allodynia threshold (second) in paclitaxel-induced neuropathic rats. Data are
expressed as mean ± SD.
Day Control (n = 6) Paclitaxel
1mg/kg(n = 6)
Lercanidipine
0.5μg/kg (n = 6)
Lercanidipine
1.0μg/kg (n = 6)
Lercanidipine
2.5μg/kg (n = 6)
01 1 .22 ±2.09 11.72 ±1.56 12.44 ±2.41 1 .61 ±2.33 10.89 ±1.54
71 2 .56 ±1.21 0 .33 ±1.32 9.72 ±1.08 10.67 ±2.15 11.94 ±1.40
14 12.78 ±2.86 8.44 ±2.14∗ 8.24 ±2.70∗ 12.83 ±1.38# 12.44 ±1.44#
21 12.44 ±2.41 8.89 ±2.22∗ 8.56 ±3.14∗ 11.78 ±1.54# 12.44 ±1.96#
28 13.61 ±.85 8.22 ±2.28∗ 8.83 ±2.87∗ 11.06 ±1.85# 11.11 ±.54#
∗P < 0.001 compared to 0 day, #P<0.01 compared to paclitaxel group.
are usually painful) and allodynia (pain due to light touch or
other stimuli that are not usually painful) [9].
In order to evaluate the mechanisms of neuropathic pain
and to ﬁnd new therapeutic approaches, diﬀerent experimental
neuropathic pain models have been developed which include
chronic constriction injury of sciatic nerve, partial sciatic nerve
ligation, and partial transaction of sciatic nerve. Current
knowledge regarding the mechanisms of neuropathic pain is
incomplete and is biased by a focus on animal models of pe-
ripheral nerve injury, and the treatment is often unsatisfac-
t o ry .I ti sa na r e ao fl a r g e l yu n m e tt h e r a p e u t i cn e e d .T h ec u r -
rent pharmacological mainstays of clinical management are
tricyclic antidepressants and certain anticonvulsants, but
these only achieve clinically signiﬁcant (>50%) pain relief in
40–60% of patients and are associated with several side
eﬀects. Opioids are generally considered to be less eﬀective
in neuropathic pain than in inﬂammatory pain [4].
Paclitaxelisoneofthemosteﬀectiveandcommonlyused
antineoplastic drugs for the treatment of solid tumours. It
has two serious side eﬀects, myelosuppression and periph-
eral neurotoxicity [10]. Paclitaxel produces a dose-limiting
painful peripheral neuropathy in a clinically signiﬁcant
number of cancer patients. Clinically, paclitaxel-induced
neurotoxicitytypicallypresentsasasensoryneuropathy,with
themostcommoncomplaintsbeingnumbness,tingling,and
burning pain. Sensory symptoms usually start symmetrically
in the feet, but sometimes appear simultaneously in both
hands and feet. Most cases resolve within months after pacli-
taxel treatment is discontinued, but the sensory abnormali-
ties and pain sometimes become a chronic problem. In ex-
perimental animals, paclitaxel can produce a dose-limiting
painful peripheral neuropathy when given intraperitoneally
andcanbeusedasamodelofperipheralneuropathytoevaluate
the eﬀect of various drugs in neuropathic pain [5].
In the present study, young Wistar rats were administered
single intraperitoneal (i.p.) injection of 1mg/Kg of paclitaxel
on four alternate days (0, 2, 4, and 6) and neuropathy was
seen at day 14.
Voltage-gated Ca2+ channels conduct Ca2+ ions into the
neuron during depolarization and have roles in synaptic
transmitter release from peripheral and central synapses,
membraneexcitability,andintracellularsignalingeventsthat
alter gene expression and lay the foundations for LTP within
spinal sensory neurons. The sensory neuron’s repertoire of
voltage-gated Ca2+ channels includes L-, N-, P/Q-, R- and
T-type channels, which subserve diﬀerent functional roles
relative to their cellular locations. L channels are key deter-
minants of membrane excitability, N and P/Q channels in-
ﬂuence transmitter release at synaptic junctions, whilst R
channels, which are particularly prevalent in nociceptive
spinal cord pathways, confer a supporting role. T channels
are low-voltage-activated channels that permit Ca2 ﬂux at
resting membrane potentials, hence their role in peacemak-
ing, neuronal bursting, and synaptic-signal boosting.
Variouspreclinicalstudiespointtoanalteredroleofvolt-
age-gated Ca2+ channels, particularly the α2δ subunit after
neuropathy, and speciﬁc blockers have been shown to dif-
ferentially attenuate the behavioral hypersensitivities and
altered dorsal horn neuronal responses that accompany ex-
perimental neuropathic pain [11–13] .T h es t u d i e sd o n et o
evaluate the action of CCBs on CNS are quite limited. Gaba-
pentin (GBP), a drug used in the clinical treatment of neuro-
pathic pain, binds to the α2δ subunit of voltage-gated Ca2+
channels and attenuates transmitter release [14]. Lercani-
dipine is a third-generation L-type calcium channel blocker
(CCB) belonging to the class dihydropyridines and is ap-
proved for the treatment of cardiovascular disorders. A
single study conducted in the Department of Pharmacology,4 Pain Research and Treatment
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Figure 1: Eﬀect of lercanidipine in various doses on cold allodynia
threshold (second) in paclitaxel-induced neuropathic rats. Data are
expressed as mean ± SD.
PGIMER, Chandigarh, reported the eﬃcacy of lercanidipine
in orofacial pain model of rat [15].
Studies have demonstrated that T-type calcium channels
may play a role in chemotherapy-induced neuropathy and
moreoveridentifyethosuximideasanewpotentialtreatment
for chemotherapy-induced pain [16–18]. There are studies
in the published literatures that have demonstrated that
agents like neurotropin [19], ganglioside [20, 21], acetyl-L-
carnitine [22] prevent and reduce paclitaxel-induced painful
neuropathy in rats.
In the present study, paclitaxel-induced neuropathy was
seen at day 14. Decrease in latency was observed in tail ﬂick
and cold allodynia, and it was persisted till 28 days. Three
doses (0.5, 1.0, 2.5μg/kg) of lercanidipine were used to pre-
vent paclitaxel-induced neuropathy in the present study, and
both of the 1.0, 2.5μg/kg doses were eﬀective in preventing
neuropathy. To the best of our knowledge, the present study
is the ﬁrst study to demonstrate the eﬀect of lercanidipine in
paclitaxel-induced neuropathy model in rat (Figures 1 and
2). But the limitation of the present study is that we have not
explored the underlying mechanism of lercanidipine. This
is the pilot study with lercanidipine, and the result provide
the view that lercanidipine may be an option for preventing
paclitaxel-induced neuropathy. Further studies with this
drugindiﬀerentneuropathicmodelsandreceptorcharacter-
ization should be done, which may provide a better answer.
5. Conclusion
Lercanidipine is a third-generation L-type calcium channel
blocker (CCB) belonging to the class dihydropyridines and
is approved for the treatment of cardiovascular disorders. To
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Figure 2: Eﬀect of lercanidipine in various doses on cold allodynia
threshold (second) in paclitaxel-induced neuropathic rats. Data are
expressed as mean ± SD.
the best of our knowledge, the present study is the ﬁrst pilot
study to demonstrate the eﬀect of lercanidipine in paclitaxel-
induced neuropathy model in rat, and the results provide
the view that lercanidipine may be an option for preventing
paclitaxel-induced neuropathy. Further studies with this
drugindiﬀerentneuropathicmodelsandreceptorcharacter-
ization should be done, which may provide a better answer.
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